PolyPid (PYPD)
(Delayed Data from NSDQ)
$3.46 USD
0.00 (0.00%)
Updated Sep 20, 2024 12:29 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PYPD 3.46 0.00(0.00%)
Will PYPD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PYPD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PYPD
PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?
Wall Street Analysts Think PolyPid Ltd. (PYPD) Could Surge 206%: Read This Before Placing a Bet
PYPD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Liquidia Technologies (LQDA) Outperforming Other Medical Stocks This Year?
All You Need to Know About PolyPid Ltd. (PYPD) Rating Upgrade to Buy
Wall Street Analysts Believe PolyPid Ltd. (PYPD) Could Rally 223%: Here's is How to Trade
Other News for PYPD
PolyPid files to sell 3.91M ordinary shares for holders
PolyPid files to sell 3.91M ordinary shares for holders
PolyPid (PYPD) Receives a Hold from Barclays
Buy Rating Affirmed for PolyPid on D-PLEX Clinical Progress and Potential Early Approval
PolyPid Ltd (PYPD) Q2 2024 Earnings Call Transcript Highlights: Financial Updates and Clinical ...